ArticleEuropean journal of nuclear medicine and molecular imaging2020
Article in European journal of nuclear medicine and molecular imaging, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 3 syntheses or guidelines pooled it, 59 citations in OpenAlex.
- The Role of Magnetic Resonance Imaging and Positron Emission Tomography/Computed Tomography in the Primary Staging of Newly Diagnosed Prostate Cancer: A Systematic Review of the Literature.European urology oncology · 2021Pooled it
- PET/MRI in prostate cancer: a systematic review and meta-analysis.European journal of nuclear medicine and molecular imaging · 2021Pooled it
- Head-to-Head Comparison ofFrontiers in oncology · 2021Pooled it
- Combining prostate-specific membrane antigen PET/CT with Memorial Sloan Kettering Cancer Center and Briganti 2012 nomograms enhances lymph node metastasis prediction in prostate cancer patients with a risk above 5.Asian journal of urology · 2026Article
- Estimation of split renal function using [EJNMMI research · 2026Article
- Examining the association between real-world extended vs. standard pelvic lymph node dissection and early and late oncologic outcomes in men undergoing radical prostatectomy.Canadian Urological Association journal = Journal de l'Association des urologues du Canada · 2025Article
- External validation of nomograms including PSMA PET information for the prediction of lymph node involvement of prostate cancer.European journal of nuclear medicine and molecular imaging · 2025Article
- Robotic-assisted super-extended pelvic lymph node dissection for prostate cancer: safety and pathologic findings.The Canadian journal of urology · 2025Article
- PSMA PET/CT based multimodal deep learning model for accurate prediction of pelvic lymph-node metastases in prostate cancer patients identified as candidates for extended pelvic lymph node dissection by preoperative nomograms.European journal of nuclear medicine and molecular imaging · 2025Article
- [Frontiers in medicine · 2025Article
- The association of quantitative PSMA PET parameters with pathologic ISUP grade: an international multicenter analysis.European journal of nuclear medicine and molecular imaging · 2024Article
- Comparison of Multiparametric MRI, [Cancers · 2023Article
- Application of machine learning algorithm in prediction of lymph node metastasis in patients with intermediate and high-risk prostate cancer.Journal of cancer research and clinical oncology · 2023Article
- Development and external validation of a multivariable [European journal of nuclear medicine and molecular imaging · 2023Article
- Gene's expression underpinning the divergent predictive value of [18F]F-fluorodeoxyglucose and prostate-specific membrane antigen positron emission tomography in primary prostate cancer: a bioinformatic and experimental study.Journal of translational medicine · 2023Article
- The efficacy ofFrontiers in oncology · 2023Article
- The prognostic value ofFrontiers in oncology · 2023Article
- The Performance of FDA-Approved PET Imaging Agents in the Detection of Prostate Cancer.Biomedicines · 2022Review
- Primary tumour PSMA intensity is an independent prognostic biomarker for biochemical recurrence-free survival following radical prostatectomy.European journal of nuclear medicine and molecular imaging · 2022Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionRadical prostatectomy with extended pelvic lymph node dissection (ePLND) is a curative treatment option for patients with clinically significant localised prostate cancer. The decision to perform an ePLND can be challenging because the overall incidence of lymph node metastasis is relatively low and ePLND is not free of complications. Using current clinical nomograms to identify patients with nodal involvement, approximately 75-85% of ePLNDs performed are negative. The aim of this study was to assess the added value of
methods
resultsOverall, pathology of ePLND specimens revealed 31 pelvic metastatic lymph nodes in 12 patients.
conclusionOur model combining PSA, Gleason score and visual lymph node analysis on
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.